BackClarity Pharmaceuticals Overview

Clarity Pharmaceuticals Receivables

Latest receivables for CU6.AX: $13M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$12.82M
↑ 26.95% YoYΔ $2.72M vs prior year quarter

Peer trimmed avg / median

Loading

Clarity Pharmaceuticals Receivables History

Loading

Clarity Pharmaceuticals vs. peers: Receivables Comparison

Loading

Clarity Pharmaceuticals Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Clarity Pharmaceuticals (CU6.AX) FAQ

As of the most recent data (June 2026), CU6.AX shows a receivables of $13M. That compares with $10M in the prior-year period — up 26.9% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CU6.AX's receivables is now $13M (was $10M) — a 26.9% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Clarity Pharmaceuticals is outperforming or lagging.

Tracking CU6.AX's receivables over time shows whether Clarity Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $13M That compares with $10M in the prior-year period — up 26.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Clarity Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $13M) with ownership activity and broader fundamentals.